Bispecific antibodies in prostate cancer therapy: Current status and perspectives

16Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Prostate carcinoma (PC) is the second most common cancer in men. When the disease becomes unresponsive to androgen deprivation therapy, the remaining treatment options are of limited benefit. Despite intense efforts, none of the T cell-based immunotherapeutic strategies that meanwhile have become a cornerstone for treatment of other malignancies is established in PC. This refers to immune checkpoint inhibition (CI), which generally reinforces T cell immunity as well as chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) that stimulate the T cell receptor/CD3-complex and mobilize T cells in a targeted manner. In general, compared to CAR-T cells, bsAb would have the advantage of being an “off the shelf” reagent associated with less preparative effort, but at present, despite enormous efforts, neither CAR-T cells nor bsAbs are successful in solid tumors. Here, we focus on the various bispecific constructs that are presently in development for treatment of PC, and discuss underlying concepts and the state of clinical evaluation as well as future perspectives.

References Powered by Scopus

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

66848Citations
N/AReaders
Get full text

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

10554Citations
N/AReaders
Get full text

Immunobiology of dendritic cells

5835Citations
N/AReaders
Get full text

Cited by Powered by Scopus

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?

29Citations
N/AReaders
Get full text

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

23Citations
N/AReaders
Get full text

An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers

22Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Heitmann, J. S., Pfluegler, M., Jung, G., & Salih, H. R. (2021, February 1). Bispecific antibodies in prostate cancer therapy: Current status and perspectives. Cancers. MDPI AG. https://doi.org/10.3390/cancers13030549

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

82%

Researcher 2

18%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

38%

Immunology and Microbiology 4

25%

Agricultural and Biological Sciences 3

19%

Biochemistry, Genetics and Molecular Bi... 3

19%

Save time finding and organizing research with Mendeley

Sign up for free